EA201890816A1 - Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc) - Google Patents
Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc)Info
- Publication number
- EA201890816A1 EA201890816A1 EA201890816A EA201890816A EA201890816A1 EA 201890816 A1 EA201890816 A1 EA 201890816A1 EA 201890816 A EA201890816 A EA 201890816A EA 201890816 A EA201890816 A EA 201890816A EA 201890816 A1 EA201890816 A1 EA 201890816A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mcrpc
- castration
- prostate cancer
- metastatic prostate
- patients
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233206P | 2015-09-25 | 2015-09-25 | |
| PCT/US2016/053387 WO2017053763A2 (en) | 2015-09-25 | 2016-09-23 | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890816A1 true EA201890816A1 (ru) | 2018-09-28 |
Family
ID=58387342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890816A EA201890816A1 (ru) | 2015-09-25 | 2016-09-23 | Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc) |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190285636A1 (enExample) |
| EP (1) | EP3353553B1 (enExample) |
| JP (1) | JP6936231B2 (enExample) |
| CN (3) | CN118443943A (enExample) |
| AU (1) | AU2016325617A1 (enExample) |
| CA (1) | CA2999911A1 (enExample) |
| EA (1) | EA201890816A1 (enExample) |
| IL (1) | IL258318A (enExample) |
| WO (1) | WO2017053763A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101926117B1 (ko) | 2017-08-18 | 2018-12-06 | 주식회사 싸이토젠 | 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법 |
| JP7717614B2 (ja) * | 2019-03-28 | 2025-08-04 | カーディフ・オンコロジー・インコーポレイテッド | Ｐｌｋ１阻害薬及び前立腺癌のｐｓａレベル |
| EP4160181A4 (en) * | 2020-05-28 | 2024-08-07 | Wang, Daoxiang | METHOD FOR PREPARING MULTIPLE STAINING SECTIONS FOR A CYTOPATHOLOGY SAMPLE |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014047285A1 (en) * | 2012-09-19 | 2014-03-27 | Paraskevi Giannakakou | Identifying taxane sensitivity in prostate cancer patients |
| CN106062561B (zh) * | 2013-09-30 | 2021-11-09 | 斯克利普斯研究院 | 为了监测前列腺癌患者中的肿瘤进化进行循环肿瘤细胞的基因型和表型分析 |
| WO2015112955A1 (en) * | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| EP3100052B1 (en) * | 2014-01-30 | 2021-03-10 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
-
2016
- 2016-09-23 WO PCT/US2016/053387 patent/WO2017053763A2/en not_active Ceased
- 2016-09-23 CA CA2999911A patent/CA2999911A1/en not_active Abandoned
- 2016-09-23 US US15/762,076 patent/US20190285636A1/en not_active Abandoned
- 2016-09-23 JP JP2018536062A patent/JP6936231B2/ja active Active
- 2016-09-23 EA EA201890816A patent/EA201890816A1/ru unknown
- 2016-09-23 AU AU2016325617A patent/AU2016325617A1/en not_active Abandoned
- 2016-09-23 EP EP16849728.7A patent/EP3353553B1/en active Active
- 2016-09-23 CN CN202410551103.0A patent/CN118443943A/zh active Pending
- 2016-09-23 CN CN202410551097.9A patent/CN118443942A/zh active Pending
- 2016-09-23 CN CN201680068025.2A patent/CN108450001A/zh active Pending
-
2018
- 2018-03-22 IL IL258318A patent/IL258318A/en unknown
-
2023
- 2023-02-27 US US18/175,427 patent/US20240036047A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118443942A (zh) | 2024-08-06 |
| WO2017053763A2 (en) | 2017-03-30 |
| AU2016325617A1 (en) | 2018-04-19 |
| EP3353553A4 (en) | 2019-04-17 |
| CN118443943A (zh) | 2024-08-06 |
| IL258318A (en) | 2018-05-31 |
| CN108450001A (zh) | 2018-08-24 |
| US20190285636A1 (en) | 2019-09-19 |
| JP6936231B2 (ja) | 2021-09-15 |
| CA2999911A1 (en) | 2017-03-30 |
| EP3353553B1 (en) | 2021-11-17 |
| JP2018535432A (ja) | 2018-11-29 |
| US20240036047A1 (en) | 2024-02-01 |
| WO2017053763A3 (en) | 2017-12-21 |
| EP3353553A2 (en) | 2018-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691505A1 (ru) | Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc) | |
| EA201891571A1 (ru) | Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания | |
| MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| EA201691496A1 (ru) | Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| EA201691352A1 (ru) | Диагностика рака легкого с помощью циркулирующих опухолевых клеток | |
| MX392671B (es) | Antagonistas de unión a pd-l1 y usos de los mismos para el tratamiento de cáncer | |
| EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
| EA201792679A1 (ru) | Способы диагностики и лечения злокачественной опухоли | |
| EA201891304A1 (ru) | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ | |
| EA201691499A1 (ru) | Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям | |
| GB2545361A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
| Zhang et al. | Negative prognostic impact of low absolute CD 4+ T cell counts in peripheral blood in mantle cell lymphoma | |
| WO2018097614A3 (ko) | 유방암 환자의 화학치료 유용성 예측 방법 | |
| MX375794B (es) | Axitinib para usarse en el tratamiento de cáncer de células renales metastásico. | |
| EA201891085A1 (ru) | Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания | |
| Shraibman et al. | Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma | |
| MX2021003214A (es) | Metodos terapeuticos y de diagnostico para el cancer de vejiga. | |
| PH12019500675A1 (en) | Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer | |
| EA201691497A1 (ru) | Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток | |
| WO2017053763A3 (en) | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) | |
| Del Gobbo et al. | The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas | |
| EA201891693A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови | |
| Xiao et al. | Patterns of failure after radical surgery among patients stage T2-3N0M0 esophageal squamous cell carcinoma potential value of postoperative radiotherapy |